CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Views
administrator
07/14/23
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Show more
Facebook Comments
No comments found